Background-There is evidence of The association between coeliac disease and Down's syndrome is now well established. The earliest reports were case study approaches which described the coexistence of the two conditions in a few patients. [1] [2] [3] [4] [5] [6] [7] As this association could occur by chance, of more relevance were studies which retrospectively surveyed larger populations, either of known cases of coeliac disease8 9 The next progression has been to prospectively survey populations of patients with Down's syndrome, using antibody screening tests to determine eligibility for biopsy." [1] [2] [3] [4] [5] [6] It is difficult to draw conclusions about the strength of the association between coeliac disease and Down's syndrome from these studies because of the lack of comparability in the findings (Table I) These studies have also raised the question of the reliability of antibody testing, particularly antigliadin antibodies. Between 24% and 50% of those biopsied were found to have coeliac disease, indicating that most antibody results were "false positives". The more recent studies have indicated that the antiendomysial antibodies are more accurate than antigliadin antibodies in determining selection for biopsy. 15 16 The present study was undertaken to examine these issues in more detail. The questions of concern were: (Table III) .
Discussion
We may now attempt to answer the questions put earlier. Firstly, there is unquestionably an increased prevalence of antigliadin antibodies in Down's syndrome. The second question, that of the prevalence of coeliac disease in Down's syndrome, requires some exploration. Two patients had unequivocal changes -the classic "flat" biopsy specimen. Seven patients had abnormal biopsy specimens; in two of these giardia organisms were seen and provided adequate explanation for the cellular infiltrate, and in five it is possible but unlikely that they were a response to giardia infestation with a scant population not recognised on microscopy. A much more likely explanation is that they represent the infiltrative lesion described by Marsh, who has vigorously promoted the view that this infiltrative stage represents a response to antigens such as gluten products and which is much more frequent than the classic "flat" biopsy sample.'7 Many years before, Weinstein noted similar infiltrative appearances in patients with dermatitis herpetiformis culminating in a "flat" biopsy sample in patients given a 20 g gluten supplement daily for 20 weeks.'8 This represents a large dose of gluten, being equivalent to eating almost a 500 g loaf of bread daily (Bread Research Institute of Australia, personal communication). Given that the five patients had raised antigliadin antibodies and lymphocytic infiltrates in their lamina propria, and three of them had lowered serum albumin concentrations, it is difficult to escape the conclusion that they, or most of them, had gluten intolerance. If this is so then up to seven of the 18 patients biopsied out of 51 patients adequately examined had coeliac disease. There are strategies to consider to confirm the gluten intolerance of patients such as these five. Rebiopsy after a period of glutenfree diet or after a period of high gluten diet such as that used by Weinstein'8 might well settle the issue. The caregivers of one of these five have attempted to implement a gluten-free diet, with equivocal results. Compliance with the diet by a severely disabled patient and his multiple caregivers has presented major logistical problems and it is difficult to justify rebiopsy when withdrawal has not been complete. The patient also has cardiac problems which have worsened since the initial biopsy, placing him at risk for procedures requiring sedation. Many of the biopsies were carried out in difficult circumstances, with sedation being difficult to achieve at the usual dosages. It needs to be recognised that endoscopical biopsy on uncooperative adults presented major challenges and pulse oximetry showed, at times, appreciable hypoxaemia. Equally, general anaesthesia was not a feasible alternative.
In summary, the prevalence of coeliac disease in our patients with Down's syndrome is at least two and probably seven of 18 patients biopsied and of 51 of the entry cohort giving a prevalence of at least 3-9% (95% CI= 0-9.2%) and as much as 13-7% (95% CI= 4.30/6-23.2%). The prevalence of coeliac disease in the Hunter region is about 29/105, so the prevalence in Down's syndrome is increased more than 100-fold (X 135-473). 19 The third question, that of the utility of the search for antigliadin antibodies, can be answered with some reservations. The antigliadin IgG test is too sensitive and the antigliadin IgA test a better discriminant.
Our study, like others reported earlier,""'6 found many "false positive" antibody results; that is, almost 50% of antibody positive patients with Down's syndrome had a normal biopsy result. As the control group did not show such a high rate of positivity this is a response specific to the Down's syndrome group. There was little correlation between actual antibody titre and biopsy result; some of the patients with Down's syndrome had very high antibody titres and a normal biopsy specimen. Given the higher number of "false positives" when using antigliadin antibodies with the patients with Down's syndrome compared with controls, we think that antiendomysial antibody is preferable.20 21 is early weaning, characteristic of the condition and associated with a five-fold increase in the incidence of coeliac disease.30 Thirdly, it is possible that the frequent gastrointestinal infections in such institutionalised patients may lead to an impairment of integrity of the small bowel. In summary, there are no data to explain the high prevalence of coeliac disease in Down's syndrome. Whether the solution lies in more intensive epidemiological studies or in events at a molecular level must remain speculative. Further investigations along these lines are warranted.
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